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Abstract: Altered expressions of mitochondria elongation factor Tu (EF-Tu) have been 
observed in certain types of cancers, including gastric cancer cell lines, but the impact of 
the alterations in gastric adenocarcinoma remains unclear. The purpose of this study was to 
investigate the expression of EF-Tu in gastric adenocarcinoma and to assess its clinical 
significance.  A  total  of  104  paired  resected  gastric  adenocarcinoma  and  corresponding 
normal  specimens  were  collected  in  this  study.  EF-Tu  expression  was  assessed  by 
immunohistochemical  staining.  The  correlation  of  EF-Tu  expression  and  patients’ 
clinicopathological parameters was statically evaluated and the prognostic significance of 
EF-Tu expression was assessed by univariate and multivariate analyses. Forty-nine out of 
104 (47.1%) gastric adenocarcinoma specimens showed high expression of EF-Tu, while 
the remaining 55 specimens showed weak or negative expression of EF-Tu. In contrast, 
EF-Tu high expression was detected in 62.5% (65 of 104) normal tissues. Down-regulation 
of  EF-Tu  was  associated  with  serosal  invasion  (P  =  0.042)  and  node  involvement   
(P  =  0.005),  and  down-regulation  of  EF-Tu  was  correlated  with  poor  overall  survival   
(P = 0.020).  In curative resection (R0) patients, there were  also significant differences   
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(P  =  0.043).  In  the  multivariate  analysis,  the  EF-Tu  expression  remained  a  significant 
independent prognostic factor (P = 0.038). Our results indicate that EF-Tu is expressed in 
both gastric adenocarcinoma and corresponding normal tissues. Down-regulation of EF-Tu 
expression is associated with advanced disease stage and EF-Tu expression maybe served 
as an independent prognostic factor. 
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1. Introduction 
Currently gastric adenocarcinoma remains one of the most common cancers worldwide, and one of 
the leading causes of cancer-related death in China [1]. Gastric adenocarcinoma encompasses many 
subtypes  with  distinct  genetic  and  biological  features.  Identification  of  new  biological  markers  to 
determine the risk of poor prognosis is important for designing treatment strategies [2,3]. 
Elongation factor Tu (EF-Tu, Tu translation elongation factor, TUFM), one of the most abundant 
proteins of the mitochondrial, plays  a key  role in the elongation process of mitochondrial protein 
biosynthesis [4]. The main function of the translation factor EF-Tu is to deliver aminoacyl-tRNA to the 
A-site on the ribosome. In addition, other functions and characteristics have been reported for EF-Tu, 
including its chaperone properties [5,6] and roles in signal transduction [7]. Expressions of EF-Tu have 
been observed in a variety of tissues with high level of expression in tissues with intrinsically active 
oxidative metabolism such as heart [8] and brain [9]. 
Recent studies have shown that the expression level of EF-Tu is altered in several types of cancers. 
Up-regulation  of  both  EF-Tu  and  the  cytoplasmic  elongation  factor  EF-1a  in  human  pancreatic 
adenocarcinoma  has  been  reported  [10,11],  whereas  absence  of  EF-Tu  expression  in  human 
hepatocellular carcinoma cell lines HepG2 was also observed [12]. These studies yielded variable and, 
in some cases, contradictive results in terms of the expression of EF-Tu in different tumor cells [11–13]. 
Furthermore, one recent study showed that EF-Tu was up-regulated in human gastric cancer cell line 
AGS compared to the rat normal gastric cell line RGM-1, and it was then proposed that EF-Tu might 
be served as potential cancer biomarkers in mitochondria [14]. 
The  purpose  of  the  present  study  was  to  examine  the  expression  status  of  EF-Tu  in  gastric 
adenocarcinoma  tissues  and  to  evaluate  whether  EF-Tu  expression  level  correlates  with  the 
clinicopathological parameters and prognosis of gastric adenocarcinoma patients. To the best of our 
knowledge, this is the first report on evaluating expression of the EF-Tu in clinical specimens of 
gastric  adenocarcinoma.  Our  results  indicate  that  EF-Tu  down-regulation  correlates  well  with 
advanced disease stage and EF-Tu expression is an independent prognostic factor. 
2. Materials and Methods 
2.1. Case Selection 
Paired specimens of gastric adenocarcinoma and corresponding normal specimens were obtained 
from 104 patients who underwent surgical resection of gastric adenocarcinoma in the department of Int. J. Mol. Sci. 2011, 12  6647 
 
 
surgical oncology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine between July 
1995  and  March  2007,  with  informed  consent  under  the  guideline  of  Hospital  Ethics  Committee. 
Among the 104 patients, 13 patients who had synchronous peritoneal metastasis were included in this 
study. The patients comprised 68 males and 36 females aged 38 to 88 years old (mean = 67.5 years 
old).  None  of  the  patients  received  any  anti-cancer  treatment  before  surgery.  Correlation  between 
expression  of  EF-Tu  and  clinicopathologic  parameters  including  age,  sex,  pTNM  pathological 
classification of the International Union against Cancer (UICC) [12], peritoneal dissemination, and 
lymph node metastasis were evaluated. 
2.2. Immunohistochemistry 
Immunohistochemical  analysis  for  EF-Tu  expression  was  performed  on  formalin-fixed, 
paraffin-embedded  sections  of  surgical  specimen.  The  slides  were  deparaffinized  in  xylene  and 
rehydrated  in  gradient  ethanol  solutions.  Endogenous  peroxidase  was  blocked  with  0.3%  H2O2  in 
methanol for 10 min. The slides were immersed in 10 mM citric buffer (pH 6.0) with heating for   
15 min for antigen retrieval. The slides were cooled at room temperature for 20 min and then washed 
with phosphate buffered saline (PBS). Nonspecific binding was blocked by preincubation with 10% 
fetal calf serum in PBS with 0.01% sodium azide, and the slides were incubated in a humid chamber 
for  1  h  with  antibody  against  EF-Tu  (mouse  monoclonal,  CBP-KK1,  Santa  Cruz;  1:200).  After 
washing three times in PBS, the slides were incubated with the EnVision-HRP complex (undiluted, 
DAKO) for 60 min. The slides were visualized with diaminobenzidine (DAKO Corp., Changzhou, 
China)  and  then  counterstained  with  hematoxylin.  For  substitute  negative  controls,  the  primary 
antibody  was  replaced  with  phosphate  buffered  saline.  Positive  controls  included  gastric 
adenocarcinomas tissue known to exhibit high levels of marker. 
All the slides were examined and scored independently by two experienced pathologists to avoid 
subjective biases. The criteria for EF-Tu expression level was as follows: no cytoplasm staining was 
given  a  score  0;  faint/barely  perceptible  cytoplasm  staining  detected  in  >25%  of  tumor  cells  was 
scored as 1+; a moderate cytoplasmic staining observed in >25% of tumor cells was scored as 2+, a 
high cytoplasmic staining observed in >25% of tumor cells was graded 3+ respectively. A score of   
0 was considered negative and 1+ was considered weak positive, whereas 2+ and 3+ were considered 
high positive. 
2.3. Follow Up 
The patients were followed up until death or until the date of last follow-up of 30 November 2007. 
Thirty-six patients (34.6%) died during the follow-up period, and the median follow-up interval was 
50.6 months (range: 3 to 127 months). 
2.4. Statistical Analysis 
All statistical analyses were conducted using the statistical program SPSS 15.0 for windows (SPSS, 
Chicago, IL, USA). Pretreatment characteristics were analyzed using the 2-tailed chi-square test, and 
the 2-tailed t test was used to evaluate correlation between EF-Tu expression and clinicopathologic Int. J. Mol. Sci. 2011, 12  6648 
 
 
parameters. Univariate analysis of patient survival was performed using Kaplan-Meier method. The 
survival curves were compared using the log-rank test. Multivariate analyses were done using logistic 
regression  and  Cox’s  proportional  hazard  model.  The  accepted  level  of  significance  was  set  as   
P < 0.05. 
3. Results 
3.1. EF-Tu Expression Correlates with Clinicopathologic Parameters 
The majority (94.2%, 98 of 104) of gastric adenocarcinomas showed positive expression of EF-Tu. 
In  a  total  of  104  gastric  adenocarcinoma  specimens,  55  (52.9%)  showed  high  EF-Tu  expression,   
39  (41.3%)  showed  weak  EF-Tu  expression  and  6  (5.8%)  showed  absence  of  EF-Tu  expression   
(Figure 1). EF-Tu was also observed in 103 (99%) corresponding normal tissues with 65 (62.5%) 
showed high expression and 38 (36.5%) showed low expression. Lymphocytes, vascular endothelial 
cells, and smooth muscle also showed high EF-Tu expression (Figure 2). 
EF-Tu  expression  was  correlated  with  depth  of  invasion,  and  node  involvement.  However,  no 
difference was found between both groups regarding sex, age, tumor differentiation, location, type of 
operation, ECOG, tumor size, distant metastasis (Tables 1 and 2). 
Figure  1.  Immunohistochemical  analysis  of  elongation  factor  Tu  (EF-Tu)  expression  in 
gastric  adenocarcinomas.  (a)  High  complete  cytoplasmic  staining  observed  in  >25%  of 
tumor cells; (b) faint/barely perceptible cytoplasmic staining detected in >25% of tumor 
cells; (c) No staining observed. 
 
C
a
n
c
e
r
 
T
i
s
s
u
e
 
N
o
r
m
a
l
 
T
i
s
s
u
e
 Int. J. Mol. Sci. 2011, 12  6649 
 
 
Figure  2.  Immunohistochemical  analysis  of  EF-Tu  expression  in  interstitial  tissue: 
(a) Smooth muscle; (b) venous endothelial cells; (c) artery endothelial cells, showed high 
EF-Tu expression. Immunohistochemical analysis of EF-Tu negative control: (d) Smooth 
muscle; (e) venous endothelial cells; (f) artery endothelial cells. 
 
Table 1. Comparison of demographic and perioperative data in gastric adenocarcinoma patients. 
  Negative/low (n = 55)  High (n = 49)  P value 
Age  54.9 ± 11.3  57.2 ± 12.5  0.329 
Gender      0.104 
Male  40 (61.5%)  28 (51.7)   
Female  15 (38.5%)  21 (48.3)   
ECOG      0.544 
0  18 (32.7)  17 (35.4)   
1  37 (67.3)  31 (62.5)   
2  0  1 (2.1)   
Type of operation      1.000 
Total gastrectomy  6 (10.9)  5 (10.2)   
Subtotal gastrectomy  49 (89.1)  44 (89.8)   
ECOG:  Eastern  Cooperative  Oncology  Group;  age  represents  as  mean  ±  SD;  values  in  the 
parenthesis are percentage. Int. J. Mol. Sci. 2011, 12  6650 
 
 
Table 2. Comparison of clinicopathologic features in gastric adenocarcinoma patients. 
  Negative/low (n = 55)  High (n = 49)  P value 
Location      0.753 
Upper body or whole  13 (23.6)  9 (18.5)   
Lower or middle body  42 (76.4)  40 (81.5)   
Tumor differentiated      0.061 
Well  7 (12.7)  2 (4.1)   
Moderate  14 (25.5)  22 (40.0)   
Poor  34 (61.8)  25 (55.9)   
Tumor size  5.3 ± 2.3  4.3 ± 2.0  0.021 
Serosal invasion      0.042 
No  14 (25.5)  22 (44.9)   
Yes  41 (74.5)  27 (55.1)   
Node involveme      0.005 
No  13 (23.6)  25 (51.0)   
Yes  42 (76.4)  24 (49.0)   
Mean no. of tLNs  21  19  0.489 
Distant metastasis      1.000 
No  48 (87.3)  43 (23.6)   
Yes  7 (12.7)  6 (23.6)   
Normal specimens EF-Tu expression      0.015 
Negative/low  27 (49.1)  12 (24.5)   
High  28 (50.9)  37 (75.5)   
tLNs indicates total retrieved Lymph Nodes; LN: Lymph Node. 
3.2. Univariate Analysis 
In  univariate  analysis  tumor  location,  tumor  size,  node  invasion,  distant  metastasis,  type  of 
operation and EF-Tu expression were associated with overall survival. Based on the expression level 
of EF-Tu, the mean overall survival time for negative/low EF-Tu expression group were 71.6 months 
and  for  high  EF-Tu  expression  group,  101.7  months,  respectively.  The  difference  in  survival  was 
significant (P = 0.020) (Figure 3a). Even in the curative resection cases, a mean overall survival time 
for negative/weak EF-Tu expression group were 79.0 months, and for high EF-Tu expression group 
106.2 months respectively. The difference in survival was also significant (P = 0.043) (Figure 3b). 
These data suggest down-regulated EF-Tu expression correlates with poor prognosis. 
3.3. Multivariate Analysis 
The  following  significant  parameters  were  entered  into  a  multivariate  analysis:  EF-Tu,  distant 
metastasis, serosal invasion, number of mLNs, number of tLNs, type of operation, age, tumor size, 
histological type, gender, tumor location. In terms of both overall and recurrence-free survivals, the 
EF-Tu  expression  was  the  independent  predictor  (hazard  ratio  0.460,  P  =  0.038  Table  3),  which 
suggests EF-Tu expression served as an independent prognostic factor. 
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Figure  3.  (a)  The  mean  overall  survival  time  for  the  negative/weak  EF-Tu  expression 
group  was  71.6  months,  and  for  the  high  EF-Tu  expression  group  was  101.7  months   
(P = 0.020); (b) In R0 (radical operation) gastric cancer, the mean overall survival time for 
the  negative/weak  EF-Tu  expression  group  was  79.0  months  and  for  the  high  EF-Tu 
expression group was106.2 months (P = 0.043). 
   
Table 3. Results of Stepwise multivariate analysis for Prognostic Factors (n = 104). Values 
in parentheses are 95% confidence intervals. * Cox proportional hazards model. 
Variable  HR  95% CI  P * value 
EF-Tu  0.460  0.220–0.960  0.038 
Distant metastasis  4.323  1.442–12.963  0.009 
Serosal invasion (yes vs. no)  6.242  1.808–21.548  0.004 
mLNs  1.082  1.001–1.169  0.047 
tLNs      0.053 
Type of operation      0.096 
Age (years) (>55 vs ≤55)      0.187 
Tumor size (≦4 cm vs >4 cm)      0.547 
Histological type (undifferentiated vs differentiated)      0.812 
Gender      0.810 
Tumor location      0.856 
HR indicates hazards ratio; 95% CI, 95% confidence interval; mLNs: metastatic lymph nodes;   
tLNs: total retrieved lymph nodes; Variables that were entered into the regression model were 
EF-Tu,  distant  metastasis,  Serosal  invasion,  mLNs,  tLNs,  type  of  operation,  age,  tumor  size, 
histological type, Gender, tumor location. Number of mLNs, and number of tLNs were consecutive 
variables; others were categorized variables. 
4. Discussion 
Elongation factor Tu (EF-Tu) is involved in mitochondrial protein synthesis, which complexes with 
GTP and transports the aa-tRNA to the programmed ribosome [15,16]. Moreover, it can participate in 
other cellular processes such as organization of mitotic apparatus, developmental regulation, aging, 
cell morphology and transformation [17–19]. Recent studies have shown that dysregulation of EF-Tu 
is involved in the oncogenic process [14]. However, both decreased and increased levels of EF-Tu 
expression have been found in different human cancers, and these contradictory results led to different Int. J. Mol. Sci. 2011, 12  6652 
 
 
conclusions for the roles of EF-Tu in carcinogenesis. In hepatocellular carcinoma, down-regulation of 
EF-Tu expression was found in cell line HepG2, while up-regulation was found in another cell line 
HCC-S102 [12]. In addition, EF-Tu was up-regulated in human gastric cancer cell line AGS compared 
to the rat normal gastric cell line RGM-1 by two-dimensional electrophoresis proteomic analysis on 
the mitochondria-enriched fractions, which may influence the function of the mitochondrial [14]. In 
our preliminary study, we also observed different levels of EF-Tu expression in some tumor cell lines, 
including high level EF-Tu expression in breast cancer cell line MCF7, leukemia cell line k562 and 
gastric cancer cell lines SGC-7901, MKN-45 and KatoIII, and low level EF-Tu expression in gastric 
cancer cell lines MKN-28 and MKN-74. All these investigations indicate that the role EF-Tu plays in 
the oncogenic process, may be very complicated. 
In  the  current  study,  we  examined  EF-Tu  expression  in  104  gastric  adenocarcinoma  cases  and 
showed that EF-Tu staining in specimens is predominantly localized on the cell membrane/cytoplasm, 
and the level of EF-Tu expression decreased in tumor specimens as compared to normal counterparts. 
Down-regulation  of  EF-Tu  expression  in  tumor  specimens  showed  a  powerful  adverse  prognostic 
effect in our study. The effect of EF-Tu expression status was independent of other known predictors, 
such  as  the  nodal  ratio,  tumor  size,  depth  of  invasion  or  distant  metastasis.  Furthermore,  EF-Tu 
expression level was associated with curative resection (R0) patients’ outcome. The interesting thing 
was that all six EF-Tu-negative patients recurred after operation. To increase case numbers in future 
may provide more clear and solid evidence. 
Although there have been several studies on EF-Tu expression in different cancer cell lines [20–22], 
no investigation on EF-Tu expression in gastric adenocarcinoma specimens and correlation analysis 
between EF-Tu and adenocarcinoma patients’ clinicopathological parameters and prognosis has been 
carried out to date. Recent molecular-profiling studies have identified EF-Tu dysregulation as a potentially 
important event in cancer development and proposed it may serve as potential cancer biomarkers in 
mechanism of the mitochondrial changes in gastric tumor cell [14], but this postulation lacks clinical 
evidence. It is not yet clear how EF-Tu expression level change affects the survival of patients with 
gastric adenocarcinoma. Since EF-Tu displays chaperone activity in the quality control of misfolded 
newly synthesized polypeptides in mitochondria in a GTP-independent manner [23,24], we speculated 
that when EF-Tu was down-regulation, the peptides synthesized from mitochondria ribosomes may be 
misfolded, which may lead to tumor development and/or progression [25,26]. 
Mitochondria  are  key  players  in  several  cellular  functions  including  growth,  division,  energy 
metabolism and apoptosis, and its dysfunction contributes to a number of human disorders and may aid 
cancer progression [27]. It is believed that gastric adenocarcinoma is associated with a severe hypoxia 
and mitochondria degeneration, when comparing with normal subjects [28,29]. EF-Tu participates in 
the elongation process of protein biosynthesis in mitochondria, and down-regulation of EF-Tu may 
suggest the dysfunctions of mitochondria, which might be another reason for poor survival in patients 
with EF-Tu down-regulation. 
One of the main characteristics of cancer cells is their rapid proliferation and this easily causes local 
hypoxic environment, due to the inability of the local vasculature to supply an adequate amount of 
oxygen.  Because  of  the  inability  of  mitochondria  to  provide  enough  ATP  for  cell  survival  under 
hypoxic  conditions,  tumor  cells  must  up-regulate  the  glycolytic  pathway  [30,31].  This  occurs  by Int. J. Mol. Sci. 2011, 12  6653 
 
 
induction of hypoxia-inducible factor 1 (HIF-1) which also suppresses mitochondrial function in tumor 
cells [32,33], suggesting a hypoxic relationship with mitochondrial dysfunction.   
In summary, we have shown that expression of EF-Tu can be used as a potential molecular marker 
to predict patient outcome in gastric adenocarcinoma patients. Our data showed that negative or low 
EF-Tu expression has a high correlation with poor survival both in univariate and multivariate analyses. 
Therefore  future  investigation  on  elucidation  of  the  precise  roles  of  EF-Tu  expression  in  gastric 
adenocarcinoma will provide new insights, which will contribute to improved diagnosis and treatment.   
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